Ophthalmology Times Staff Reports

June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.

A successful Type B Rare Disease Evidence Principles meeting confirms the pivotal study design, opening a potential BLA pathway on 6-month efficacy data, with dosing expected to begin in the fourth quarter of 2026.

Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.

The trial over-enrolled and finished approximately 4 months ahead of initial projections, with 52-week topline data now expected in the second half of 2027.

Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.

The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.

Three-year gene therapy data, an FDA reversal in wet AMD, light-powered dry eye treatment, a new macular supplement, and progress in childhood glaucoma—our review breaks down the 5 May 2026 stories that matter.

The study, led by researchers at Keio University School of Medicine, measured near add power in 6258 patients aged 40 to 79.

Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has received FDA approval for use in ophthalmic surgery.

The FDA has approved loteprednol etabonate ophthalmic suspension 0.25% for short-term treatment of the signs and symptoms of dry eye disease.

This action will result in 2 separate companies,

Provider portal features an updated enrollment form, and potential for a 60-second benefit verification. 

The company promotes two and adds another employee as it names three vice presidents.

Pseudophakic patients may benefit from a fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences), the company tells a United Kingdom committee.

A cellular-level adaptive optics retinal camera (rtx1, Imagine Eyes) has received CE mark approval in the European Union.

A new sealant (ReSure, Ocular Therapeutix) will be studied for clear corneal incision closure after cataract extraction or IOL placement.

Improved efficacy and dosing convenience are the aims of a new drug delivery system incorporating a cationic polymer and formulated with ketorolac.

New data presented at the European Society of Retina Specialists meeting suggest that ranibizumab is effective in patients with AMD, DME, and RVO.

Newly published research gives ophthalmologists a reason to encourage their adult patients with visual field loss in both eyes to be more physically active.

Researchers have identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigments (RP).

Glaucoma and age-related macular degeneration (AMD) research grants have been awarded to Wilmer Eye Institute by the American Health Assistance Foundation.

The Welch Allyn facility in Beaverton, OR, earned Leadership in Energy and Environmental Design (LEED) certification from the U.S. Green Building Council.

William M. Moore has been named interim president and chief executive officer of Iridex Corp. Moore succeeds Dominik Beck.

Implantable contact lens and preloaded IOL manufacturing will move to California in a consolidation project now under way at STAAR Surgical.

Glaucoma may be a significant predictor of depression, according to research published in the American Journal of Ophthalmology.

The FDA approved OptiMedica's Catalys Precision for creating single-plane and multi-plane arc incisions in the cornea during cataract surgery.

Ocular Therapeutix Inc. is initiating a phase II clinical trial of OTX-TP2, a 2-month travoprost punctum plug for treating ocular hypertension and glaucoma.